# Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

> **NCT01728077** · PHASE3 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 26 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT01728077
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728077, "Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT01728077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*